Study of Anlotinib and Bemocizumab as Pre-Surgery Treatment for Resectable Esophageal Squamous Cell Carcinoma to Improve Surgery Outcomes and Disease-Free Survival

What this Trial Is About

Researchers are evaluating the effectiveness and safety of anlotinib combined with bemocizumab as a neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma ESCC. The goal is to improve the rates of complete pathological response and margin-negative resection in patients undergoing surgery, and to enhance disease-free survival after surgery. This prospective, single-arm clinical study will provide new treatment options and guidance for locally advanced esophageal cancer. Participants will receive 3 to 4 cycles of neoadjuvant therapy before surgery, consisting of bemocizumab at 1200 mg every 3 weeks and anlotinib at 8 mg daily for 14 days per cycle. Surgery will be scheduled 4 to 6 weeks after completing the neoadjuvant therapy, and will typically involve a three-incision thoracoabdominal laparoscopic esophagectomy, with other surgical approaches used as appropriate. Postoperative adjuvant therapy will be given based on each patients condition. During the study, participants will undergo pathological evaluation after surgery to determine the primary outcome of pathological complete response. Follow-up will continue for 5 years to assess outcomes such as overall survival and margin-negative resection rates. Patients will attend regular clinical visits for assessments, blood and tissue sample collection, and monitoring of safety and disease status throughout the study period.

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)